Anixa Biosciences Inc key statistics and ratios

In fiscal 2024, Anixa Biosciences Inc had return on equity of -56.6%, an operating margin of -6586.2%, debt equal to 0.0% of equity and a current ratio of 8.54. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anixa Biosciences Inc: financial ratios, annual
Fiscal year	2010Oct 2010	2011Oct 2011	2012Oct 2012	2013Oct 2013	2014Oct 2014	2015Oct 2015	2016Oct 2016	2017Oct 2017	2018Oct 2018	2019Oct 2019	2021Oct 2021	2023Oct 2023	2024Oct 2024
Operating margin	−718.3%	−501.2%	−439.8%	<−999%	−137.5%	−10.2%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%
Net margin	−708.3%	−735.5%	−452.4%	<−999%	−261.9%	−14.9%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%
Free-cash-flow margin	−329.5%	−72.3%	−334.3%	—	−65.1%	14.1%	<−999%	<−999%	−387.6%	<−999%	−964.5%	<−999%	<−999%
Return on equity	−112.6%	—	—	—	—	−30.4%	−166.1%	−112.4%	—	—	−63.7%	−32.8%	−56.6%
Return on assets	−51.5%	−78.9%	−59.5%	−181.6%	−132.5%	−15.0%	−67.0%	−69.4%	−183.4%	−182.8%	−60.9%	−31.8%	−53.3%
Asset turnover	0.07	0.11	0.13	0.07	0.51	1.01	0.04	0.05	0.15	0.04	0.02	0.01	0.01
Current ratio	2.74	1.48	0.51	0.38	3.49	11.61	7.25	7.89	4.38	4.11	28.35	12.50	8.54
Debt to equity	0.0%	0.0%	—	—	61.2%	14.9%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	—	n/m	n/m	n/m	n/m	n/m	n/m	—	—	—	—	—
R&D as % of revenue	411.6%	311.5%	235.3%	—	—	7.7%	518.8%	440.7%	612.4%	>999%	>999%	>999%	>999%
SG&A as % of revenue	395.4%	286.3%	304.6%	>999%	174.8%	59.6%	903.3%	>999%	621.3%	>999%	—	—	—
Capital spending as % of revenue	0.3%	0.9%	0.2%	—	0.2%	0.6%	48.8%	8.3%	3.5%	70.2%	0.0%	0.0%	0.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Anixa Biosciences Inc: financial ratios, quarterly
Quarter	2021 Q2Apr 2021	2021 Q3Jul 2021	2021 Q4Oct 2021	2022 Q1Jan 2022	2022 Q2Apr 2022	2023 Q2Apr 2023	2023 Q3Jul 2023	2023 Q4Oct 2023
Operating margin	<−999%	—	—	−756.3%	—	<−999%	—	—
Net margin	<−999%	—	—	−746.4%	—	<−999%	—	—
Free-cash-flow margin	<−999%	—	—	−233.3%	—	−384.3%	—	—
Current ratio	26.66	30.67	28.35	19.58	27.39	17.83	14.22	12.50
R&D as % of revenue	>999%	—	—	358.3%	—	475.2%	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

12 /100

Weak moat

How hard Anixa Biosciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -65.9% of total assets over 10 years.
Durability 10 / 20

Operating margin has been a median -594.9%; its worst year was -317265.8%.
Discipline 0 / 20

The diluted share count rose 87.4% over five years; stock-based pay has been a median 1024.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Anixa Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anixa Biosciences Inc.